The Thymidylate Synthase pipeline drugs market research report outlays comprehensive information on the Thymidylate Synthase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Thymidylate Synthase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Infectious Disease, and Dermatology which include the indications Pancreatic Cancer, Gastric Cancer, Cryptococcal Meningitis, Bacterial Infections, and Actinic (Solar) Keratosis. It also reviews key players involved in Thymidylate Synthase targeted therapeutics development with respective active and dormant or discontinued products.
The Thymidylate Synthase pipeline targets constitutes close to 20 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 5, 1, and 8 respectively. Similarly, the universities portfolio in Phase I, Preclinical, and Discovery comprises 1, 1, and 1 molecule.
Thymidylate Synthase overview
Thymidylate synthase catalyzes the methylation of deoxyuridylate to deoxythymidylate, using 10-methylenetetrahydrofolate (methylene-THF) as a cofactor. This function maintains the dTMP (thymidine-5-prime monophosphate) pool critical for DNA replication and repair. The enzyme has been of interest as a target for cancer chemotherapeutic agents. It is considered to be the primary site of action for 5-fluorouracil, 5-fluoro-2-prime-deoxyuridine, and some folate analogs.
For a complete picture of Thymidylate Synthase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
